FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia

Psychopharmacology

Volumn 175, Issue 1, 2004, Pages 7-17

  Boeckler, Frank ^a,b   Russig, Holger ^a   Zhang, Weining ^a   Löber, Stefan ^b   Schetz, John ^c   Hübner, Harald ^b   Ferger, Boris ^a   Gmeiner, Peter ^b   Feldon, Joram ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Atypical antipsychotic; Catalepsy; Complete antagonist; Dopamine D4 selective; Dopamine turnover; FAUC 213; Locomotor activity; Prepulse inhibition

Indexed keywords

2 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YLMETHYL]PYRAZOLO[1,5 A]PYRIDINE; AMPHETAMINE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 4 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CATALEPSY; CONTROLLED STUDY; DOPAMINE METABOLISM; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; LOCOMOTION; MALE; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TURNOVER TIME;

AMPHETAMINE; ANIMALS; BRAIN; CATALEPSY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; NEURONS; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STARTLE REACTION; TIME FACTORS;

EID: 4544380870     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1782-1     Document Type: Article

References (42)

1. 4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 752:26-34
2. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
3. Bakshi VP, Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283:666-674
4. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234-258
5. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283:1256-1263
6. 4 receptors. J Neurochem 63:62-65
7. 4 dopamine receptor in rat brain with sequence specific antibodies. Mol Brain Res 45:1-12
8. De La Garza R II, Madras BK (2000) [(3)H]PNU-101958, a D(4) dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. Synapse 37:232-244
9. Dulawa SC, Gross C, Stark KL, Hen R, Geyer MA (2000) Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition. Neuropsychopharmacology 22:650-659
10. Ellenbroek BA, Peeters BW, Honig WM, Cools AR (1987) The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 93:343-348
11. 4.4 receptor. Br J Pharmacol 124:889-896
12. 4.4 receptors expressed in CHO cells. Br J Pharmacol 128:613-620
13. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498
14. Geyer MA, Krebs-Thomson K, Varty GB (1999) The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology 21:S134-S142
15. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154
16. Hübner H, Kraxner J, Gmeiner P (2000) Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments. J Med Chem 43:4563-4569
17. Karoum F, Egan MF (1992) Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br J Pharmacol 105:703-707
18. Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107-128
19. Kuschinsky K, Hornykiewicz O (1972) Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19:119-122
20. 3H]NGD 94-1 study. Mol Psychiatry 3:528-533
21. Löber S, Hübner H, Utz W, Gmeiner P (2001) Rationally based efficacy tuning of selective dopamine D4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl) piperazin-1-ylmethyl]pyrazolo[1,5-a] pyridine (FAUC 213). J Med Chem 44:2691-2694
22. Mansbach RS, Brooks EW, Sanner MA, Zorn SH (1998) Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 135:194-200
23. 4 receptor. Mol Brain Res 29:157-162
24. 4 receptor in human cerebral cortex and striatum. J Neurochem 66:915-919
25. 4 receptors in GABAergic neurons of the primate brain. Nature 381:245-248
26. 4 gene expression in human brain. Neurosci Lett 234:147-150
27. 35S]-Guanosine-5′-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191
28. 4 receptor. J Pharmacol Exp Ther 283:636-647
29. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, New York
30. 3H]NGD 94-1. J Pharmacol Exp Ther 282:1020-1027
31. Remington G, Kapur S (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148:3-15
32. 4 receptors in drug-treated schizophrenia. Eur J Pharmacol 281:R5-R6
33. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
34. Rowley M, Bristow LJ, Hutson PH (2001) Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 44:477-501
35. Seeman P (1995) Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 10:5-13
36. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291:59-66
37. 4 receptors elevated in schizophrenia. Nature 365:441-445
38. 125I]epidepride. Eur J Pharamcol 286:R3-R5
39. 4 receptors. Neuropsychopharmacology 16:93-110
40. Snyder SH (1996) Drugs and the brain. Scientific American Library, New York
41. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
42. Westerink BHC (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem Int 7:221-227